Emergent Biosolutions
EBS
EBS
176 hedge funds and large institutions have $1.03B invested in Emergent Biosolutions in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 71 increasing their positions, 67 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
35% less call options, than puts
Call options by funds: $370K | Put options by funds: $568K
63% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 40
Holders
176
Holding in Top 10
–
Calls
$370K
Puts
$568K
Top Buyers
| 1 | +$122M | |
| 2 | +$15.9M | |
| 3 | +$10.7M | |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.43M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$7.38M |
Top Sellers
| 1 | -$16M | |
| 2 | -$12.3M | |
| 3 | -$9.33M | |
| 4 |
D.E. Shaw & Co
New York
|
-$7.39M |
| 5 |
LCP
Lombardia Capital Partners
Pasadena,
California
|
-$6.88M |